Company intelligence / Profile preview
Stemedica Cell Technologies
San Diego, California, United Statesstemedica.com ↗
- Ownership
- Private
- Employees
- ~45
- Development stage
- Other
01
Overview
Stemedica has conducted multiple Phase 1 and Phase 2 trials. Notable results include a Phase 2a clinical trial for Alzheimer's disease using itMSC which met its primary safety endpoint and showed preliminary signals of cognitive stabilization. Their stroke trials have also demonstrated safety and improved motor function in some cohorts.
- Therapeutic areas
- CardiovascularNeurologyDermatology
- Modalities
- Stem cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Alamo Bio-HealthGlobal Stem Cells Group
Beyond the preview
Go deeper on Stemedica Cell Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stemedica Cell Technologies.